Related Experiment Video
Updated: Aug 12, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Predictors for severe cardiac complications after hematopoietic stem cell transplantation
M Sakata-Yanagimoto1, Y Kanda, M Nakagawa
1Department of Cell Therapy & Transplantation Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Insights
The cumulative dose of anthracyclines is a key predictor of severe cardiac complications after hematopoietic stem cell transplantation. Avoid anthracycline use within two months before transplant to reduce cardiac risks.
Area of Science:
- Hematology
- Cardiology
- Oncology
Background:
- Predicting cardiac complications post-hematopoietic stem cell transplant (HSCT) remains challenging.
- Previous studies on pre-transplant factors show inconsistent results.
Purpose of the Study:
- To identify pre-transplant risk factors for severe cardiac complications after HSCT.
- To evaluate the predictive value of various clinical and diagnostic parameters.
Main Methods:
- Retrospective analysis of 164 HSCT recipients.
- Assessment of pre-transplant factors including anthracycline dosage and timing.
- Evaluation of cardiac complications using Bearman criteria and relative tachycardia.
Main Results:
- Eight patients (4.8%) experienced severe cardiac complications (Grade III-IV).
- Higher cumulative anthracycline dose and recent anthracycline use (<60 days) were associated with increased risk.
- Relative tachycardia was also a significant predictor.
- Multivariate analysis identified cumulative anthracycline dose as the sole independent risk factor.
Conclusions:
- Cumulative anthracycline dose is the strongest predictor of severe cardiac complications post-HSCT.
- Anthracycline administration should be avoided within two months prior to transplantation to mitigate cardiac risks.
Abstract:
The value of pre-transplant factors for predicting the development of cardiac complications after transplantation has been inconsistent among studies. We analyzed the impact of pre-transplant factors on the incidence of severe cardiac complications in 164 hematopoietic stem cell transplant recipients. We identified eight patients (4.8%) who experienced grade III or IV cardiac complications according to the Bearman criteria. Seven died of cardiac causes a median of 3 days after the onset of cardiac complications. On univariate analysis, both the cumulative dose of anthracyclines and the use of anthracyclines within 60 days before transplantation affected the incidence of severe cardiac complications (P=0.0091 and 0.011). The dissociation of heart rate and body temperature, which reflects "relative tachycardia", was also associated with a higher incidence of cardiac complications (P=0.024). None of the variables obtained by electrocardiography or echocardiography were useful for predicting cardiac complications after transplantation, although the statistical power might not be sufficient to detect the usefulness of ejection fraction. On a multivariate analysis, the cumulative dose of anthracyclines was the only independent significant risk factor for severe cardiac complications. We conclude that the cumulative dose of anthracyclines is the most potent predictor of cardiac complications and the administration of anthracyclines should be avoided within two months before transplantation.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Pathophysiology of Heart Failure
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy

